Bausch & Lomb Corp
BLCO- Exchange
- NYSE
- Industry
- Ophthalmic Goods
- SEC CIK
- 0001860742
In the last 90 days, Bausch & Lomb Corp insiders filed 0 open-market purchases and 2 sales; 99 institutions reported holding it in 13F filings for Q2 2026, worth $638.7M in total; 3 superinvestors hold it, including Icahn Capital and Oaktree Capital.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Bausch & Lomb Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 2 filings
- 2 insiders, $1.19M in total
- Insiders trading
- 2
- Net value
- −$1.19M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Bausch & Lomb Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Trebbi Barbara | Director | 11,776 | Aug 14, 2026 | 1 |
| Paul Laurence E | Director | 11,776 | Aug 14, 2026 | 1 |
| Chersi Robert J | Director | 11,776 | Aug 14, 2026 | 1 |
| Munsch Frederick | SVP, Controller and CAO | 45,831 | Aug 12, 2026 | 6 |
| Von Eschenbach Andrew C. | Director | 63,733 | Aug 10, 2026 | 3 |
| Stewart Andrew J. | President, GPIC | 103,211 | Aug 7, 2026 | 4 |
| Hashad Yehia | EVP of R&D and CMO | 187,350 | Aug 7, 2026 | 5 |
| Eldessouky Sam | EVP and CFO | 393,527 | Aug 7, 2026 | 6 |
| Bonnefoy Luc | President, Surgical | 103,801 | Aug 7, 2026 | 6 |
| Bailey A Robert D | EVP & Chief Legal Officer | 264,241 | Aug 7, 2026 | 5 |
| Saunders Brent L | Chairman of the Board and CEO | 1,256,037 | Aug 7, 2026 | 6 |
| Collis Steven H | Director | 42,003 | May 28, 2026 | 4 |
| Paulson John | Director | 89,823 | May 28, 2026 | 4 |
| Ling Karen | Director | 61,518 | May 28, 2026 | 2 |
| Ross Thomas W. Sr. | Director | 85,233 | May 28, 2026 | 2 |
| Robertson Russel C | Director | 94,260 | May 28, 2026 | 5 |
| Kavanagh Sarah B | Director | 69,541 | May 28, 2026 | 1 |
| Bernier Nathalie D. | Director | 85,505 | May 28, 2026 | 1 |
| Alfonso Eduardo | Director | 31,072 | May 28, 2026 | 4 |
| Icahn Brett | Director | 61,147 | May 28, 2025 | 0 |
| Hu Gaoxiang | Director | 61,147 | May 28, 2025 | 0 |
| De Schutter Richard U | Director | 32,952 | Apr 2, 2024 | 0 |
| Ackermann Christina | Please see remarks | 146,677 | Mar 3, 2023 | 0 |
| Gordon Joseph F | Please see remarks | 125,702 | Mar 3, 2023 | 0 |
| Bausch Health Companies Inc. | 10% Owner | 310,449,643Indirect | Jun 2, 2022 | 0 |
| Papa Joseph C | CEO & Chairman | 472,222 | May 9, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 (view filing)7:06 PM ET | Aug 10 | 2 days | Munsch FrederickSVP, Controller and CAO | SSaleCommon Shares, No Par Value | −52.9K | $16.78 | −$887.7K | −53.6%45.8K after | |
| Aug 10, 2026 (view filing)8:57 PM ET | Aug 6-7 | 4 days | Von Eschenbach Andrew C.Director | SSaleCommon Shares, No Par Value | −18.6K | $16.53 | −$306.7K | −22.6%63.7K after | 2 lots |
| Mar 10, 2026 (view filing) | Mar 6 | 4 days | Bailey A Robert DEVP & Chief Legal Officer | PPurchaseCommon Shares, No Par Value | +14.6K | $17.15 | +$250.4K | +6.7%231.9K after | |
| Mar 10, 2026 (view filing) | Mar 6 | 4 days | Eldessouky SamEVP and CFO | PPurchaseCommon Shares, No Par Value | +4.00K | $17.13 | +$68.5K | +1.0%403.1K after | |
| Mar 10, 2026 (view filing) | Mar 6 | 4 days | Saunders Brent LCEO and Chairman of the Board | PPurchaseCommon Shares, No Par Value | +14.7K | $17.14 | +$252.0K | +1.5%966.6K after | |
| Mar 4, 2026 (view filing) | Mar 3 | 1 day | Ross Thomas W. Sr.Director | PPurchaseCommon Shares, No Par Value | +4.50K | $17.68 | +$79.6K | +7.5%64.9K after | |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Alfonso EduardoDirector | PPurchaseCommon Shares, No Par Value | +4.30K | $17.90 | +$77.0K | +81.8%9.55K after | |
| Mar 3, 2026 (view filing) | Feb 27 | 4 days | Von Eschenbach Andrew C.Director | PPurchaseCommon Shares, No Par Value | +4.36K | $18.31 | +$79.9K | +7.0%66.5K after | |
| Feb 24, 2026 (view filing) | Feb 23 | 1 day | Collis Steven HDirector | PPurchaseCommon Shares, No Par Value | +15.0K | $17.81 | +$267.1K | +285.4%20.3K after | |
| Feb 24, 2026 (view filing) | Feb 20 | 4 days | Robertson Russel CDirector | PPurchaseCommon Shares, No Par Value | +4.40K | $17.90 | +$78.8K | +6.5%72.4K after | |
| Feb 23, 2026 (view filing) | Feb 19 | 4 days | Ling KarenDirector | PPurchaseCommon Shares, No Par Value | +4.00K | $17.74 | +$71.0K | +10.6%41.7K after | |
| May 27, 2025 (view filing) | May 22 | 5 days | Saunders Brent LCEO and Chairman of the Board | PPurchaseCommon Shares, No Par Value | +22.0K | $11.28 | +$248.2K | +3.2%719.2K after | |
| May 6, 2025 (view filing) | May 2 | 4 days | Von Eschenbach Andrew C.Director | PPurchaseCommon Shares, No Par Value | +1.70K | $11.76 | +$19.9K | +4.2%41.7K after | |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Saunders Brent LCEO and Chairman of the Board | PPurchaseCommon Shares, No Par Value | +32.3K | $15.66 | +$505.0K | +5.7%595.2K after | |
| Jun 2, 2022 (view filing) | Jun 1 | 1 day | Bausch Health Companies Inc.10% Owner | SSaleCommon Shares, No Par Value | −4.55M | $17.06 | −$77.6M | −1.4%310.4M after | |
| May 12, 2022 (view filing) | May 10 | 2 days | Bausch Health Companies Inc.10% Owner | SSaleCommon Shares, No Par Value | −35.0M | $17.06 | −$597.1M | −10.0%315.0M after |